Cue Biopharma is a biotechnology company based in Cambridge, MA that is focused on developing immunotherapies for the treatment of cancer. Their innovative approach involves creating therapeutics that mimic the natural signals of the immune system, known as "Cues," to activate tumor-specific T cells in the patient's body and target cancer cells specifically. By harnessing the power of the patient's own immune system, Cue Biopharma aims to provide more effective and safe treatments for cancer.
With a pipeline of product candidates and ongoing clinical trials, Cue Biopharma is dedicated to advancing the field of immunotherapy. Their unique platforms, including Immuno-STAT, Neo-STAT, and RDI-STAT, enable the company to address the specificity and diversity of the human immune system, offering potential breakthroughs in the fight against cancer. By activating the immune system against cancer cells, Cue Biopharma's immunotherapies have the potential to revolutionize cancer treatment and improve patient outcomes.
Generated from the website